Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)

Background Sotrovimab, a monoclonal antibody with efficacy against SARS-CoV-2 including certain Omicron variants, has been used in treatment of mild-moderate COVID-19. Limited data exists regarding its use in pregnant women. Methods Electronic medical record review of pregnant COVID-19 patients treated with sotrovimab from 12/30/21 − 1/31/22 (Yale New Haven Health Hospital System [YNHHS]) was performed. Included were pregnant individuals ≥ 12 years, weighing ≥ 40 kg, with positive SARS-CoV-2 test (within 10 days). Those receiving care outside YNHHS or receiving other SARS-CoV-2 treatment were excluded. We assessed demographics, medical history, and Monoclonal Antibody Screening Score (MASS). The primary composite clinical outcome assessed included emergency department (ED) visit < 24 h, hospitalization, intensive care unit (ICU) admission, and/or death within 29 days of sotrovimab. Secondarily, adverse feto-maternal outcomes and events for neonates were assessed at birth or through the end of the study period, which was 8/15/22. Results Among 22 subjects, median age was 32 years and body mass index was 27 kg/$ m^{2} $. 63% were Caucasian, 9% Hispanic, 14% African-American, and 9% Asian. 9% had diabetes and sickle cell disease. 5% had well-controlled HIV. 18%, 46%, and 36% received sotrovimab in trimester 1, 2, and 3, respectively. No infusion/allergic reactions occurred. MASS values were < 4. Only 12/22 (55%) received complete primary vaccination (46% mRNA-1273; 46% BNT162b2; 8% JNJ-78,436,735); none received a booster. Conclusions Pregnant COVID-19 patients receiving sotrovimab at our center tolerated it well with good clinical outcomes. Pregnancy and neonatal complications did not appear sotrovimab-related. Though a limited sample, our data helps elucidate the safety and tolerability of sotrovimab in pregnant women..

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:23

Enthalten in:

BMC infectious diseases - 23(2023), 1 vom: 26. Apr.

Sprache:

Englisch

Beteiligte Personen:

Tuan, Jessica J. [VerfasserIn]
Sharma, Manas [VerfasserIn]
Kayani, Jehanzeb [VerfasserIn]
Davis, Matthew W. [VerfasserIn]
McManus, Dayna [VerfasserIn]
Topal, Jeffrey E. [VerfasserIn]
Ogbuagu, Onyema [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

COVID-19
Monoclonal antibodies
Omicron
Pregnancy
Sotrovimab

Anmerkungen:

© The Author(s) 2023

doi:

10.1186/s12879-023-08198-9

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2134716487

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?